Clinical Trial

Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 5, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
Persons without a spleen are susceptible to potentially lethal infections from certain bacteria, with pneumococcus being the most prevalent. Vaccines are provided to help protect against these infections, though they do not so with certainty. Trauma patients who sustain an injury to their spleen currently have three treatment options available for the treating surgeon - nonoperative management, embolization, or removal of the spleen. The purpose of this study is to investigate the antibody response to pneumococcal vaccine in patients undergoing these modes of therapy.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2014-09-04; most recent amendment 2025-12-03.
Status change: Active, Not Recruiting → Recruiting 2014-12-01
Trial Details
NCT Number NCT02232191
Lead Sponsor University of California, Davis
Conditions Asplenia
Enrollment 75 participants
Start Date 2014-12
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-12-05